NE

Next-Gen Live Biotherapeutics

2 known investors

anciliabio.com ↗

Ancilia uses CRISPR technology to engineer bacterial products with resistance to destructive viruses, enabling their use as live biotherapeutics. The company's CoVE and EPIC platforms computationally identify viromes and design bacterial therapies immune to specific viral threats.

Investors · 2

SN

Snatched VenturesSan Francisco

SP

Spacecadet VenturesKent County